Avista Capital Partners Invests in eMolecules

eMolecules Acquires Specs Compound Handling B.V.

May 25, 2023

Healthcare Services

eMolecules, a San Diego–based chemical compound search-and-fulfillment platform, has acquired Specs Compound Handling B.V., a Netherlands-headquartered provider of compound reformatting, repository and management services. The acquisition expands eMolecules' global compound reformatting and inventory management footprint—adding European and US facilities—and is supported by eMolecules' existing investors, including Avista Capital Partners.

eMolecules Acquires Synple Chem AG

September 24, 2024

Biotechnology

eMolecules, a San Diego-based provider of a chemical compound search-and-fulfillment platform and a portfolio company of Avista Healthcare Partners, has acquired Synple Chem AG, an automated chemical synthesis systems and services provider headquartered near Zurich, Switzerland. The acquisition adds Synple's automation technology and a virtual compound library of more than 7 trillion tractable compounds to eMolecules' existing offering, expanding its capabilities as a one-stop shop for compound procurement, management and automation for drug discovery customers.

Avista SPAC (APAC) to Combine with Ligand's OmniAb in Spin-off and Business Combination

October 24, 2022

Biotechnology

Ligand Pharmaceuticals will spin off its OmniAb antibody discovery business to shareholders and OmniAb will merge with Avista Public Acquisition Corp. II (APAC), making OmniAb a standalone, publicly-traded company. Avista Capital Partners has committed up to $115 million of investment and Ligand will contribute $15 million, providing the combined company with significant cash reserves to support growth and continued platform development.

Cambrex Acquires Avista Pharma Solutions

January 2, 2019

Pharmaceuticals

Cambrex Corporation completed the acquisition of Avista Pharma Solutions from Ampersand Capital Partners in a transaction announced November 20, 2018 and completed January 2019 (reported consideration about $252 million). The deal brings Avista’s early‑stage drug development, analytical/testing and finished dosage capabilities (sites in Longmont, CO; Durham, NC; Agawam, MA; and Edinburgh, UK) into Cambrex’s global CDMO network to expand capabilities and cross‑sell services.

Avista Capital Partners Acquires Taconic Biosciences

November 1, 2022

Biotechnology

Avista Capital Partners has acquired Taconic Biosciences from H.I.G. Capital. Taconic, a Rensselaer, New York–based provider of genetically engineered murine research models and related preclinical services, will leverage Avista's healthcare investing expertise to pursue organic growth and strategic acquisitions in the GEMs market.

eMolecules Acquires Frontier Scientific Inc. and Frontier Agricultural Sciences Inc.

September 7, 2022

Pharmaceuticals

eMolecules, a PE-backed provider of a chemistry search-and-fulfillment platform, has acquired Frontier Scientific Inc. (FSI) and Frontier Agricultural Sciences Inc. (FAS). The acquisitions expand eMolecules' capabilities in compound/sample management, analytical and procurement services and provide an entry into agricultural chemistry/entomology research markets.